Abcodia is an innovative company engaged in the validation and discovery of molecular biomarkers for disease diagnosis and screening.
The company has exclusive commercial rights to the UKCTOCS longitudinal biobank that represents one of the largest collections of prospective serum samples in the world. The collection is derived from more than 200,000 initially healthy volunteers, many of whom went on to develop cancer. Using this resource, Abcodia is working with many industrial and academic groups to advance tests for the early detection and screening of cancer.Abcodia works alongside University College London, one of the world's leading multidisciplinary universities and in partnership with diagnostic, pharmaceutical and technology companies to exploit a unique prospective serum bank for the purpose of ethical biomarker validation and discovery.
The company swept the board at Startups Awards 2012 scooping three top prizes, as well as being honoured as the overall ‘NatWest Startups Business of the Year’, for its pioneering work in cancer screening. It won every award it was shortlisted for.
CEO, Dr Julie Barnes has over 20 years experience of the Pharmaceutical and Biotechnology industry, including 15 years experience of early R&D with GlaxoSmithKline. More recently Julie was director and Chief Scientific Officer at BioWisdom, a healthcare technology company.
Her mix of scientific and commercial experience in large pharmaceutical and small start-ups and academic network brings a strong understanding of what is required to successfully lead Abcodia as an ethical and collaborative organisation.
In March 2013, Abcodia appointed Olle Nilsson as its consultant to provide industry related expertise and help to accelerate the commercialisation of Abcodia’s cancer screening programmes.
